Ethical challenges of deactivation of cardiac devices in advanced heart failure

Current Heart Failure Reports

Volumn 11, Issue 2, 2014, Pages 119-125

  Chamsi Pasha, Hassan ^a   Chamsi Pasha, Mohammed A ^b   Albar, Mohammed Ali ^c  

^a KING FAHD ARMED FORCES HOSPITAL   (Saudi Arabia)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c International Medical Center   (Saudi Arabia)

Author keywords

Bioethics; Cardiac devices; Cardiac resynchronization therapy; End of life; Ethics; Heart failure; Implantable cardioverter defibrillator; Left ventricular assist device

Indexed keywords

ARTICLE; CARDIOMYOPATHY; CLINICAL DECISION MAKING; DEVICE SAFETY; DISEASE COURSE; DISTRESS SYNDROME; GROUPS BY AGE; HEART ASSIST DEVICE; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR ASSIST DEVICE; MEDICAL ETHICS; PATIENT AUTONOMY; PRACTICE GUIDELINE; QUALITY OF LIFE; SUDDEN CARDIAC DEATH; ETHICS; INFORMED CONSENT; TERMINAL CARE; TREATMENT WITHDRAWAL;

DEFIBRILLATORS, IMPLANTABLE; ETHICS, MEDICAL; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; INFORMED CONSENT; PRACTICE GUIDELINES AS TOPIC; TERMINAL CARE; WITHHOLDING TREATMENT;

EID: 84903614445     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-014-0194-8     Document Type: Article

References (44)

1. Ben Gal T, Jaarsma T. Self-care and communication issues at the end of life of recipients of a left-ventricular assist device as destination therapy. Curr Opin Support Palliat Care. 2013;7(1):29-35.
2. Tanner CE, Fromme EK, Goodlin SJ. Ethics in the treatment of advanced heart failure: palliative care and end-of-life issues. Congest Heart Fail. 2011;17(5):235-40.
3. •• Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012;125(15):1928-52. A roadmap for when and how to have conversations with patients to support shared decision-making.
4. Kramer DB, Mitchell SL, Brock DW. Deactivation of pacemakers and implantable cardioverter-defibrillators. Prog Cardiovasc Dis. 2012;55(3):290-9.
5. Writing Committee Members, Francis GS, Greenberg BH, et al. ACCF/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced heart failure and cardiac transplant: a report of the ACCF/AHA/ACP task force on clinical competence and training. Circulation. 2010;122(6):644-72.
6. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117(21):e350-408. (Pubitemid 351771339)
7. Carlsson J, Paul NW, Dann M, Neuzner J, Pfeiffer D. The deactivation of implantable cardioverter-defibrillators: medical, ethical, practical, and legal considerations. Dtsch Arztebl Int. 2012;109(33-34):535-41.
8. • Wright GA, Klein GJ, Gula LJ. Ethical and legal perspective of implantable cardioverter defibrillator deactivation or implantable cardioverter defibrillator generator replacement in the elderly. Curr Opin Cardiol. 2013;28(1):43-9. This review stresses the point that health professionals are reluctant to discuss end-of-life planning with ICD patients.
9. Goldstein NE, Lampert R, Bradley E, Lynn J, Krumholz HM. Management of implantable cardioverter defibrillators in end-oflife care. Ann Intern Med. 2004;141(11):835-8. (Pubitemid 39601176)
10. Fromme EK, Stewart TL, Jeppesen M, Tolle SW. Adverse experiences with implantable defibrillators in Oregon hospices. Am J Hosp Palliat Care. 2011;28(5):304-9.
11. Magyar-Russell G, Thombs BD, Cai JX, et al. The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. J Psychosom Res. 2011;71(4):223 -31.
12. Wu EB. The ethics of implantable devices. J Med Ethics. 2007;33(9):532-3.
13. Padeletti L, Arnar DO, Boncinelli L, et al. EHRA expert consensus statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace. 2010;12(10):1480-9.
14. Goldstein NE, Mehta D, Siddiqui S, et al. "That's like an act of suicide" patients' attitudes toward deactivation of implantable defibrillators. J Gen Intern Med. 2008;23 Suppl 1:7-12. (Pubitemid 350295388)
15. Stewart GC, Weintraub JR, Pratibhu PP, et al. Patient expectations from implantable defibrillators to prevent death in heart failure. J Card Fail. 2010;16(2):106-13.
16. Morgenweck CJ. Ethical considerations for discontinuing pacemakers and automatic implantable cardiac defibrillators at the end-of-life. Curr Opin Anaesthesiol. 2013;26(2):171-5.
17. •• Kirkpatrick JN, Gottlieb M, Sehgal P, Patel R, Verdino RJ. Deactivation of implantable cardioverter defibrillators in terminal illness and end of life care. Am J Cardiol. 2012;109(1):91-4. This study highlights the lack of consensus among patients with an ICD on its deactivation.
18. Raphael CE, Koa-Wing M, Stain N, Wright I, Francis DP, Kanagaratnam P. Implantable cardioverter-defibrillator recipient attitudes towards device deactivation: how much do patients want to know? Pacing Clin Electrophysiol. 2011;34(12):1628-33.
19. Kelley AS, Reid MC, Miller DH, Fins JJ, Lachs MS. Implantable cardioverter-defibrillator deactivation at the end of life: a physician survey. Am Heart J. 2009;157(4):702-8.e1.
20. Waterhouse E, Ahmad F. Do implantable cardioverter defibrillators complicate end-of-life care for those with heart failure? Curr Opin Support Palliat Care. 2011;5(4):307-11.
21. Rady MY, Verheijde JL. When is deactivating an implanted cardiac device physician-assisted death? Appraisal of the lethal pathophysiology and mode of death. J Palliat Med. 2011;14(10):1086-8. discussion 1089-90.
22. Lampert R, Hayes DL, Annas GJ, et al. HRS expert consensus statement on the management of cardiovascular implantable electronic devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm. 2010;7(7):1008-26.
23. Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/ HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary. Heart Rhythm. 2008;5(6):934-55.
24. Abi-Samra FM. Cardiac implantable electrical devices: bioethics and management issues near the end of life. Ochsner J. 2011;11(4):342 -7.
25. Kini V, Kirkpatrick JN. Ethical challenges in advanced heart failure. Curr Opin Support Palliat Care. 2013;7(1):21-8.
26. •• Buchhalter LC, Ottenberg AL, Webster TL, Swetz KM, Hayes DL, Mueller PS. Features and outcomes of patients who underwent cardiac device deactivation. JAMA Intern Med. 2014;174(1):80-5. This study describes the features and outcomes of 150 patients who underwent CIED deactivations.
27. Kirklin JK, Naftel DC, Pagani FD, et al. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation? J Thorac Cardiovasc Surg. 2012;144(3):584-603. discussion 597-8.
28. Bruce CR. A review of ethical considerations for ventricular assist device placement in older adults. Aging Dis. 2013;4(2):100-12.
29. Yuan N, Arnaoutakis GJ, George TJ, et al. The spectrum of complications following left ventricular assist device placement. J Card Surg. 2012;27(5):630-8.
30. McClung JA. End-of-life care in the treatment of advanced heart failure in the elderly. Cardiol Rev. 2013;21(1):9-15.
31. Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J. 2006;151(2):444-50. (Pubitemid 43144748)
32. • Boothroyd LJ, Lambert LJ, Ducharme A, et al. Challenge of informing patient decision making: what can we tell patients considering long-term mechanical circulatory support about outcomes, daily life, and end-of-life issues? Circ Cardiovasc Qual Outcomes. 2014;7(1):179-87. Project initially designed for QuebecMinistry of Health, but authors shared their findings with the broader heart failure community.
33. McIlvennan CK, Allen LA. To DT or not to DT, that is the question: working toward a comprehensive, patientcentered perspective on left ventricular assist device for destination therapy. Circ Cardiovasc Qual Outcomes. 2014;7(1):13-4.
34. Swetz KM, Freeman MR, AbouEzzeddine OF, et al. Palliative medicine consultation for preparedness planning in patients receiving left ventricular assist devices as destination therapy. Mayo Clin Proc. 2011;86(6):493-500.
35. Dudzinski DM. Ethics guidelines for destination therapy. Ann Thorac Surg. 2006;81(4):1185-8.
36. Bruce CR, Brody B, Majumder MA. Ethical dilemmas surrounding the use of ventricular assist devices in supporting patients with endstage organ dysfunction. Methodist Debakey Cardiovasc J. 2013;9(1):11-4.
37. Mueller PS, Swetz KM, Freeman MR, et al. Ethical analysis of withdrawing ventricular assist device support. Mayo Clin Proc. 2010;85(9):791-7.
38. Rady MY, Verheijde JL. Ethical challenges with deactivation of durable mechanical circulatory support at the end of life: left ventricular assist devices and total artificial hearts. J Intensive Care Med. 2014;29(1):3-12.
39. Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11(5):433-43.
40. Swetz KM, Cook KE, Ottenberg AL, Chang N, Mueller PS. Clinicians' attitudes regarding withdrawal of left ventricular assist devices in patients approaching the end of life. Eur J Heart Fail. 2013;15(11):1262-6.
41. Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Society forHeart and Lung Transplantation guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32(2):157-87.
42. Gafford EF, Luckhardt AJ, Swetz KM. Deactivation of a left ventricular assist device at the end of life #269. J Palliat Med. 2013;16(8):980-2.
43. Schaefer KG, Griffin L, Smith C, May CW, Stevenson LW. An interdisciplinary checklist for left ventricular assist device deactivation. J Palliat Med. 2014;17(1):4-5.
44. •• Kapa S, Mueller PS, Hayes DL, Asirvatham SJ. Perspectives on withdrawing pacemaker and implantable cardioverter-defibrillator therapies at end of life: results of a survey of medical and legal professionals and patients. Mayo Clin Proc. 2010;85(11):981-90. First report of clinicians' attitudes and practices regarding LVAD deactivation in patients approaching death.